These data suggest that overexpression of Bcl3 contributes to tumour progression in p53mut breast cancers irrespective of prior chemotherapeutic intervention, suggesting that these patients may benefit most from Bcl3-targetting therapies, which based on our data presented here would have the additional benefit of inducing apoptosis and not senescence. Here, BCL3 is linked to breast carcinoma.